X-chromosome terminal deletion in a female with premature ovarian failure: Haploinsufficiency of X-linked genes as a possible explanation by Ferreira, Susana I et al.
RESEARCH Open Access
X-chromosome terminal deletion in a female with
premature ovarian failure: Haploinsufficiency of
X-linked genes as a possible explanation
Susana I Ferreira
1, Eunice Matoso
1,4, Marta Pinto
1, Joana Almeida
2, Thomas Liehr
3, Joana B Melo
1,5,
Isabel M Carreira
1,4,5*
Abstract
Background: Premature ovarian failure (POF) has repeatedly been associated to X-chromosome deletions. FMR1
gene premutation allele’s carrier women have an increased risk for POF. We intent to determine the cause of POF
in a 29 year old female, evaluating both of these situations.
Methods: Concomitant analysis of FMR1 gene CGG repeat number and karyotype revealed an X-chromosome
terminal deletion. Fluorescence in situ further characterized the breakpoint. A methylation assay for FMR1 gene
allowed to determine its methylation status, and hence, the methylation status of the normal X-chromosome.
Results: We report a POF patient with a 46,X,del(X)(q26) karyotype and with skewed X-chromosome inactivation of
the structural abnormal X-chromosome.
Conclusions: Despite the hemizygosity of FMR1 gene, the patient does not present Fragile X syndrome features,
since the normal X-chromosome is not subject to methylation. The described deletion supports the hypothesis
that haploinsufficiency of X-linked genes can be on the basis of POF, and special attention should be paid to X-
linked genes in region Xq28 since they escape inactivation and might have a role in this disorder. A full clinical
and cytogenetic characterization of all POF cases is important to highlight a pattern and help to understand which
genes are crucial for normal ovarian development.
Background
Premature ovarian failure (POF) is an early ovarian dys-
function characterized by the cessation of menses before
the age of 40 years [1,2] that affects 1% of women [3].
The diagnosis is established by the presence of FSH (fol-
licle stimulating hormone) serum level higher than 40
mIU/ml [4], detected on at least two occasions a few
weeks apart [5]. Although the exact etiology is still
unknown, several causes have been associated with POF
and may include autoimmunity, infections, iatrogenesis
and a strong genetic component, that can vary from sin-
gle gene alterations to chromosome abnormalities [6].
X;autosome balanced translocations and X-chromo-
some deletions have been reported in POF patients,
leading to the identification of two main critical regions
for normal ovarian function on the long arm of this
chromosome, specifically at Xq13-q21 [7] and Xq26-q27
[4,8]. In the case of X;autosome balanced translocations,
these can either lead to gene disruption at the rearran-
gement breakpoints, or to a position effect alteration,
changing the normal expression of genes involved in
ovarian function [9]. X-linked genes known to escape
inactivation can also be responsible for the occurrence
of POF associated with total or partial monosomies of
the X-chromosome, reflecting a situation of haploinsuf-
ficiency for those genes [9].
One of the genes known to be associated with POF is
FMR1 (Fragile X mental retardation), located at Xq27.3
and responsible for Fragile X Syndrome (FXS). It is a
form of X-linked mental retardation caused by the
expansion of an instable CGG repeat in the 5′ untrans-
lated region of the gene [1,10]. The syndrome occurs
when the number of the repeats exceeds 200, being
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any medium, provided the original work is properly cited.denominated as full mutation alleles. This is responsible
for hypermethylation and gene inactivation, leading to
absence of FMRP (Fragile X mental retardation protein)
and, consequently, causing mental retardation [11]. Men
with full mutation alleles are always affected, whereas
only one third of women are so, due to X-chromosome
inactivation [10]. Several studies have been associating
FMR1 premutation alleles, which may have 55 to 200
CGG repeats, and POF, with approximately 20% of pre-
mutation carrier women being affected [11]. Since full
mutation carriers do not have an increased risk for ovar-
ian dysfunction, the molecular mechanism underlying
the association between POF and premutation alleles,
although still unravelled, should not be related to the
absence or reduction of FMRP [12].
The present case was referred as part of a study group
of women with POF for the evaluation of their karyo-
types and association to the FMR1 gene CGG repeat
number. We report a case of a 29 year old woman with
a de novo Xq26 to Xqter deletion that includes FMR1
gene associated with POF. Besides having only one func-
tional allele prone to suffer inactivation, she has no FXS
symptoms.
Results
FMR1 repeats determination
FMR1 gene CGG repeat number evaluation revealed the
presence of only one allele (Figure 1). A woman with a
normal karyotype would have three peaks for this analy-
sis, the first one corresponding to the X-chromosome
and the other two corresponding to the two alleles of
FMR1 gene. After repeating the analysis, in order to
exclude an amplification failure during PCR reaction,
the result was confirmed, being present only one allele
with 20 CGG repeats.
Cytogenetic analysis
GTG high resolution banded metaphase spreads from
the subject were analyzed and revealed a large terminal
deletion in the long arm of one of the X-chromosomes
in all 10 metaphases studied (Figure 2A). Conventional
cytogenetics results suggest a probable deletion break-
point between bands Xq25-q26, being her final karyo-
type 46,X,del(X)(q25~q26). The subject’sm o t h e r
karyotype was normal. As the father had already
deceased it was not possible to perform cytogenetics
analysis.
Fluorescence in situ hybridization
F I S Ha n a l y s i sw i t ht h es u b t e l o m e r i cs p e c i f i cp r o b e
DXYS61 showed only one signal for Xqter in all meta-
phases scored, confirming the conventional banding
cytogenetic findings (Figure 2B). The integration of
M C Ba n dB A Cp r o b e sr e s u l t sa l l o w e du st oc o n c l u d e
with more precision that the deletion breakpoint is at
Xq26 (Figure 3). The breakpoint was between 128.660
Mb and 133.964 Mb.
FMR1 methylation analysis
This analysis revealed that the X-chromosome subjected
to methylation was the one with the qter deletion, as all
probes with HhaI recognition site were digested, mean-
ing that they were not methylated in the normal allele
present (Figure 4). Although visual analysis was quite
conclusive, the methylation status was further analyzed
with the Coffalyser software which revealed a
Figure 1 Electropherogram of FMR1 gene CGG repeat number analysis in the patient with Xqter deletion. The first peak with higher
signal intensity (1) corresponds to the X-chromosome gender specific fragment and the second one (2) to the normal FMR1 allele with 20 CGG
repeats. There is a missing third peak due to the deletion. The remaining peaks with lower intensity correspond to ROX1000 size standard.
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methylation analysis excluded allele drop out as a possi-
ble explanation for the presence of only one allele in the
FMR1 CGG repeat number PCR analysis [13]. If two
alleles were present, in a homozygous pattern (a) or a
normal allele and a full mutation allele (b) the MS-
MLPA result would be clearly different. The existence
of a second allele would always be detected by the pre-
sence of methylation, at a lower percentage due to nor-
mal X inactivation (a), or at a higher percentage in due
to both X inactivation and full mutation allele methyla-
tion (b).
Discussion
X-chromosome deletions have been associated with
POF for more than a decade, with two X-chromosome
regions, named POF1 and POF2, mainly associated
with POF. POF1 region limits are not consensual
among literature, as some authors define it as Xq23-
q27 [8], whereas others define it from Xq26 to Xq28
[14]. POF2 region is well established between Xq13.3-
q21 [7]. Most of X-chromosome abnormalities asso-
ciated with POF described in this region are X;auto-
some balanced translocations, with80% of the
chromosome breakpoints disrupting Xq21 [15]. How-
ever, women with deletions involving this gene-poor
region are not affected by POF, being the most plausi-
ble explanation a position effect on autosomal ovary-
specific genes translocated to the X-chromosome, and
not an involvement of X-linked genes [15].
Figure 2 Conventional and molecular cytogenetics results. A - Partial karyogram of GTG banded X-chromosomes of the patient. The arrow
indicates the region of the breakpoint in the X-chromosome. B - Dual colour FISH with the subtelomeric specific probes showing the normal X-
chromosome and the deleted X-chromosome (on the right).
Figure 3 FISH results. A - MCB image showing the normal and the
deleted X-chromosome. B - Image with the results of the specific
hybridization of the BAC clones that delimited the deletion
breakpoint (RP4-753P9 is present and RP11-11I8 is absent). Each
chromosome pair has is own legend relatively to the clones used
and their fluorescence colours.
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being associated with POF, with several cases already
described, and, in most of them, the same deletion is
present in two or even three generations of the same
family. As illustrated in Figure 5, Krauss et al.i n1 9 8 7
reported an interstitial deletion 46,XX,del(X)(pter ®
q21.3::q27 ® qter) in a three generation family affected
by POF and in 1991 Veneman et al. reported a mother
and her daughter, both with POF, and an Xq25 to Xqter
deletion [16,17]. Davison et al. (1998) published a 46,X,
del(X)(q26) karyotype in both mother and daughter with
POF at 28 and 26 years old, respectively; Rosseti et al.
(2004) reported an interstitial deletion 46,X,del(X)(q26
® q28) in two affected women, with secondary amenor-
rhea at 17 and 22 years old, and her mother, with POF
at 43 years old [18,19]. Fimiani et al. (2006) also
reported the case of both mother and daughter with
POF at 43 and 26 years old, respectively, both with a 46,
X,del(X)(q26.2q28) karyotype, after the report by Egger-
man et al. (2005) of a mother and daughter with a 46,X,
del(X)(q27.2 or q27.3) karyotype and POF at 36 and 28
years old, respectively [20,21]. The same figure illus-
trates four additional cases reported by Rizzolio [15].
These reports raise the question that factors other than
the deletion might be involved in POF, since women
with the same deletion manifest POF at a different
Figure 4 Electropherograms of MS-MLPA results. A - Corresponds to the undigested sample, with arrows pointing out probes with HhaI
restriction site. B - Illustrates the restriction pattern of the digested samples, where probes with HhaI restriction site are absent.
Figure 5 Schematic representation of Xq. The dotted lined represent the extension of the deletions described in the literature and of the
reported case.
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not [19].
In the present case, the mother has a normal karyo-
type and as the father had already deceased, it was not
possible to evaluate if the deletion was de novo or inher-
ited from the father. However, this deletion in a male
would be incompatible with life, and so, we can safely
hypothesize that the deletion is de novo.
The absence of Fragile X syndrome features in this
woman was quite intriguing to us since, with only one
functional allele, which according to Lyon hypotheses
should be inactivated in 50% of cells, there would be a
reduction to half in FMRP levels [22]. A methylation
assay performed to access the methylation status of the
unique FMR1 allele present resulted in a negative
methylation pattern. This allows us to conclude that
the normal X-chromosome is active, whereas the
deleted X-chromosome was preferentially inactivated,
explaining the absence of Fragile X symptoms, as there
are normal levels of FMRP. Cells with the abnormal X-
chromosome active would have a deficiency in gene
products from the deleted region, explaining the nega-
tive selection against such cells, resulting in skewed X-
chromosome inactivation (XCI) whenever there is a
structural abnormality of one of the X homologous
[22].
Carrel and Willard (2005) obtained, from fibroblast
cells, an expression profile for the genes located in the
inactive X-chromosome (Xi) revealing that about 25% of
genes escape inactivation being expressed at different
levels and from different regions of the chromosome
[23]. One of such clusters of genes expressed from Xi
maps to the gene-rich region Xq28, where the expres-
sion level may reach 50% [23].
Altogether, these results suggest that haploinsuffiency
of the genes located in the deleted region is a promising
explanation for the POF scenario, especially when it
involves Xq28. The lack of expression of those deleted
genes that normally escape X inactivation may compro-
mise ovarian function. To further evaluate this situation
it would be important to perform X inactivation status
assays in every women with X-chromosome deletion
and POF, and, as if expected, a skewed XCI pattern is
observed, this would further support the hypothesis of
haploinsufficiency of the deleted genes. MS-MLPA for
FMR1 gene can be a valuable tool for this assessment,
whenever deletion involves Xq27 region, as it is a fast
and easy to perform technique, allowing the achieve-
ment of precise results. Oral contraceptives prescribed
to our patient might have delayed the diagnosis of the
POF condition that could have manifested earlier taking
into account her menstrual patterns. This suggests that
contraceptive therapy provided her the adequate hormo-
nal levels and mitigate the menopausal symptoms due
to an eventual ovarian insufficiency, what may imply
that genes involved in the deletion can have a function
at this level. One of the patients reported by Rosseti et
al. (2004) has a similar clinical history, as she had irre-
gular menses, started to take pill at 19, and when she
stopped, at 22 years old, she had amenorrhea [19]. Yes-
haya and colleagues interestingly reported that microde-
letion syndromes could be associated with altered
replication patterns of genes not associated with the
aberrant chromosome [12]. We can not discard that the
Xq terminal deletion observed in our patient causes
altered replication timing of genes associated with POF.
However, if this would be the case, other X-chromo-
some deletions would be associated with POF. It would
be interesting to study the replication time of other
patients with POF due to X deletions [24].
The time during development when skewed X-chro-
mosome inactivation takes place can also influence the
onset of POF, since woman with the same deletion
manifest POF at different ages and sometimes with dif-
ferent severities. Understanding how this happens and
which gene(s) are necessary in a double dosage expres-
sion can lead to an improvement in reproductive knowl-
edge and to the implementation of strategies to delay or
prevent premature ovarian failure, allowing women to
preserve her reproductive life.
Nevertheless, it is thought that 5-10% of these women
will be able to conceive and will need appropriate advice
due to high risk of fragile X syndrome or POF in their
descendents [25]. Preconceptual counseling should be
offered to those women giving them full disclosure
about the risks of transmitting the disease and possible
preventive measures [25]. In addition, prenatal testing
through amniocentesis or chorionic villus sampling
should be recommended for pregnant women carriers of
the fragile X mutation or premutation.
Recently new assisted reproduction techniques asso-
ciated with preimplantation genetic diagnosis (PGD)
performed after an in-vitro fertilization cycle (IVF), gave
t h eo p p o r t u n i t yf o ras e l e c t i o no fe m b r y o sf r e eo ft h e
premutation or full mutation [25].
In our case, at the present time, the only reproductive
alternatives that could be undertaken include IVF with
oocyte donation or allotransplantation of ovarian tissue.
To summarize, these data reflect how important it is
to report all cases with POF and X-chromosome dele-
tions and their complete clinical history, in order to
highlight a pattern and try to understand which
regions are in fact crucial for normal ovarian develop-
ment. Special attention should be paid to Xq28 region
due to the knowledge that genes on this region escape
from methylation in the Xi and also due to the
increased number of POF patients with deletions invol-
ving this region.
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Subject
A 29 year old woman was referred from the gynecology
department of our local maternity due to premature
ovarian failure. She had menarche at 11 years, experi-
enced oligomenorrhea and at 14 years old she fulfilled
the diagnosis criteria for polycystic ovarian syndrome
and received a prescription of oral contraceptives. Try-
ing to get pregnant, she suspended medication 15 years
later, but she neither got pregnant or menstruated
again. Hormonal analysis revealed an FSH level of 155.5
mIU/ml, LH of 62.7 mIU/ml and 16 pg/ml for E2.T h e
patient had no history of autoimmune diseases or sur-
geries. Her mother did not report a past history of sub-
fertility and experienced menopause at 50 years. This
woman is part of a group of patients with premature
ovarian failure recruited for a study to access the asso-
ciation between this condition and FMR1 gene CGG
repeat number. The study was approved by the medical
board of the hospital and all participants gave their writ-
ten informed consent.
FMR1 gene CGG repeats determination
Genomic DNA was extracted from peripheral blood
lymphocytes using Jetquick blood and cell culture DNA
Midi Spin kit (Genomed, Löhne, Germany). DNA con-
centration and purity were measured using a Nano-
Drop1000 Spectrophotometer (Thermo Scientific,
Waltham, USA). The sample was analysed with Abbot
Fragile X kit (Abbot, Illinois, USA), which consists of a
PCR reaction specific to determine the number of CGG
repeats present at FMR1 gene. A PCR reaction of 20 μl
of final volume containing 13 μlo fH i g hG CP C RB u f -
fer, 0.8 μlo fFMR1 primers, 0.6 μl of gender primers,
1.2 μl of TR PCR enzyme mix and 3 μlo fg e n o m i c
DNA (67 ng/ul) was performed in an Applied Biosys-
tems ABI 2720 Thermal Cycler (Applied Biosystems,
Foster City CA, USA). The PCR conditions used were
15 cycles of 98.5°C for 10 s, 58°C for 1 min and 75°C
for 6 min, followed by 15 cycles starting at 98.5°C for 10
s, 56°C for 1 min and 75°C for 6 min. PCR products
were purified with CleanUp Enzyme mix and the alleles
were sized using an automated sequencer ABI Prism
310Genetic Analyser (Applied Biosystems) by compari-
son with the size standard Rox1000, both products from
Abbott (Abbott).
Cytogenetic analysis
Peripheral blood samples were collected and metaphase
chromosomes were prepared according to standard
cytogenetic procedures [26]. GTG high resolution
banded chromosomes were analyzed using a Nikon
Eclipse microscope (Nikon Instruments, Badhoevedorp,
Netherlands) coupled with the Cytovision system
(Applied Imaging International Lda, Newcastle upon
Tyne, UK).
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
according to standard procedures, using specific probes
for subtelomeric Xq (DXYS61) and Xp (DXYS129)
(Cytocell, Cambridge, UK) chromosomal regions. A total
of 10 metaphases were analyzed with a Nikon Eclipse
fluorescence microscope (Nikon) coupled with the Cyto-
vision system (Applied Imaging International Lda).
To further characterize the breakpoint, multicolour
banding (MCB) was performed using seven partial chro-
mosome painting (pcp) probes described in Weise et al.
2008 [27]. The 10 metaphases scored were analysed
using a Zeiss Axioplan fluorescence microscope (Zeiss,
Jena, Germany) with MetaSystems (Isis) software
(Altlussheim, German). Six BAC (bacterial artificial
chromosomes) clones were also used in order to clarify
the breakpoint. The analysis software was the same used
for MCB. Table 1 summarizes the BAC clones used and
their location on the X-chromosome.
FMR1 methylation analysis
Methylation-Specific Multiplex Ligation-Dependent
Probe Amplification (MS-MLPA) was performed using
the SALSA MS-MLPA MEO29-B1 kit (MRC-Holland,
Amsterdam, Netherlands). Genomic DNA, 300 ng, was
mixed with 1 μl of denaturation buffer and MLPA pro-
tocol was performed according to the manufacturers’
instructions. PCR reactions were carried out on an
Applied Biosystems ABI 2720 Thermal Cycler (Applied
Biosystems). Samples were analysed by capillary electro-
phoresis on an ABI Prism 310 Genetic Analyser
(Applied Biosystems) and Genescan software (Applied
Biosystems) was used to extract the quantitative data.
These were analyzed with Coffalyser analysis software
(MRC-Holland, Amsterdam, Netherlands) to determine
methylation status.
The aim of this analysis was to determine the degree
of methylation of the only FMR1 allele present, localized
Table 1 Characteristics of the BAC clones used for FISH
analysis
Clone Start (Mb) End (Mb) Location Insert Size (bp)
RP4-753P9 128,544 128,660 Xq25 116560
RP11-11I8 133,964 134,153 Xq26.3 188357
RP1-48G12 141,595 141,794 Xq27.3 199015
RP11-103M23 153,345 153,519 Xq28 174233
Built at the UCSC Genome Browser, version NCBI3537/hg17 and accessed at
June 26
th 2010.
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methylation-sensitive restriction enzyme HhaI to deter-
mine the degree of methylation, by comparing digested
and undigested samples of the same patient. Unmethy-
lated probes with HhaI recognition site will be digested,
and hence will disappear in the sample subject to diges-
tion, whereas methylated probes won’tb ed i g e s t e da n d ,
thus, will be present after PCR amplification. As the
subject has only one allele, the degree of methylation of
FMR1 gene is indicative of the degree of methylation of
the normal X-chromosome.
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